Acta Scientific Microbiology (ISSN: 2581-3226)

Volume 9 Issue 3 March 2026

Review Article

Emerging Therapeutic Approaches for Combating Antimicrobial-Resistant Infectious Pathogens

Emmanuel Nkansah[1], Micheal Abimbola Oladosu[2]*, Moses Adondua Abah[3], Abimbola Mary Oluwajembola[2], Fwangmun Ezekiel Gushit[4], Olaide Ayokunmi Oladosu[5], Adesola Esther Adeneye[6] and Bukola Oluwaseyi Olufosoye[7]

[1]*Department of Accounting, Economics and Finance, School of Business, La Sierra University, Riverside, CA, USA*

[2]*Department of Chemical Sciences, Faculty of Science, Anchor University, Ayobo, Ipaja, Lagos, Nigeria*

[3]*Department of Biochemistry, Faculty of Pure and Applied Sciences, Federal University of Wukari, Wukari, Taraba State, Nigeria*

[4]*Department of Public Health, Faculty of Health Science, Ahmadu Bello University, Zaria, Kaduna State, Nigeria*

[5]*Department of Computer Science, Faculty of Science and Technology, Babcock University, Ilishan, Nigeria*

[6]*Department of Biological Sciences, Faculty of Science, Anchor University, Ayobo, Ipaja, Lagos, Nigeria*

[7]*Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria*

***Corresponding Author:** Micheal Abimbola Oladosu, Department of Chemical Sciences, Faculty of Science, Anchor University, Ayobo, Ipaja, Lagos, Nigeria.

DOI: 10.31080/ASMI.2026.09.1585

Received: February 16, 2026

Published: February 28, 2026

Abstract

The emergence and rapid dissemination of antimicrobial-resistant (AMR) pathogens pose a critical threat to global public health, undermining decades of progress in treating infectious diseases. Traditional antibiotic discovery pipelines have stagnated, necessitating innovative therapeutic strategies to combat resistant infections. This review examines emerging approaches for addressing AMR, including bacteriophage therapy, CRISPR-based antimicrobial systems, antimicrobial peptides, nanoparticle-mediated drug delivery, immunotherapeutic interventions, and novel antibiotic development strategies. We synthesise recent advances from 2020-2025, highlighting their mechanisms of action, clinical potential, and current limitations. Furthermore, we discuss combination therapeutic strategies and the integration of artificial intelligence in drug discovery. The convergence of these innovative approaches offers promising avenues for circumventing resistance mechanisms and developing next-generation antimicrobial therapeutics. Addressing AMR requires a multifaceted approach combining novel treatment modalities, improved diagnostic tools, and enhanced antimicrobial stewardship programs to preserve the efficacy of both existing and emerging therapeutics.

Keywords: Antimicrobial Resistance; Bacteriophage Therapy; CRISPR-Cas Systems; Antimicrobial Peptides; Nanoparticles; Immunotherapy; Novel antibiotics

Introduction

Antimicrobial resistance represents one of the most pressing challenges in modern medicine, threatening to reverse decades of medical advancement. The World Health Organisation (WHO) has identified AMR as one of the top ten global public health threats, with resistant infections causing an estimated 1.27 million deaths annually [1]. The inappropriate use of antibiotics in healthcare, agriculture, and aquaculture has accelerated resistance development, while the declining rate of novel antibiotic discovery has created a critical therapeutic void [2]. Multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) organisms now complicate treatment regimens across diverse clinical settings, from intensive care units to community-acquired infections [3].

The economic burden of AMR is substantial, with healthcare costs and productivity losses estimated at billions of dollars globally [4]. Without effective interventions, projections suggest that AMR could cause 10 million deaths annually by 2050, surpassing cancer as a leading cause of mortality [5]. This crisis necessitates innovative therapeutic strategies that circumvent traditional resistance mechanisms and exploit alternative targets in bacterial physiology.

Recent scientific advances have unveiled promising therapeutic modalities that operate through mechanisms distinct from conventional antibiotics. These emerging approaches include bacteriophage therapy, which leverages viral predators of bacteria; CRISPR-based systems that target resistance genes; antimicrobial peptides that disrupt bacterial membranes; nanoparticle carriers that enhance drug delivery; immunotherapies that augment host defenses; and novel antibiotic classes with unique mechanisms of action [6,7]. This review examines these innovative strategies, synthesising recent progress and discussing their potential to reshape the antimicrobial therapeutic landscape.

Bacteriophage therapy

Mechanisms and therapeutic potential

Bacteriophages (phages) are viruses that specifically infect and lyse bacterial cells through highly specific host recognition mechanisms. These naturally occurring bacterial predators offer several advantages over conventional antibiotics, including high specificity, self-replication at infection sites, and potential effectiveness against biofilms [8]. Recent clinical trials have demonstrated the feasibility and safety of phage therapy in treating MDR infections, including those caused by *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Escherichia coli* [9].

Engineered phages represent an evolution of natural phage therapy, incorporating synthetic biology approaches to enhance therapeutic efficacy. These modifications include enhanced host range, improved stability, and incorporation of antimicrobial genes that disrupt resistance mechanisms [10]. Phage-derived enzymes, particularly endolysins, have shown promise as standalone antimicrobials capable of rapidly degrading bacterial cell walls [11]. The development of phage cocktails targeting multiple resistance mechanisms simultaneously offers a strategy to prevent resistance emergence during treatment [12]. Figure 1 shows the schematic representation of the bacteriophage infection cycle and therapeutic mechanisms



Figure 1: Schematic representation of bacteriophage infection cycle and therapeutic mechanisms.

This figure should illustrate the lytic cycle, including phage attachment to bacterial surface receptors, DNA injection, phage replication, and bacterial lysis. Include comparison with conventional antibiotic mechanisms and depict engineered phage modifications.

CRISPR-based antimicrobial systems

Targeted resistance gene elimination

CRISPR-Cas systems have emerged as powerful tools for precise genetic manipulation of bacterial populations. These systems can be programmed to target and cleave specific DNA sequences, including antibiotic resistance genes carried on plasmids or chromosomes [13]. The specificity of CRISPR-based antimicrobials allows selective elimination of resistant bacteria while preserving beneficial microbiota, a significant advantage over broad-spectrum antibiotics [14].

Delivery mechanisms for CRISPR-based therapeutics remain a critical challenge, with bacteriophages, plasmids, and nanoparticles being explored as vehicles. Recent advances in programmable nucleases, including Cas9, Cas12, and Cas13 variants, have expanded the targeting capabilities and efficiency of these systems [15]. Additionally, CRISPR technology can be employed to re-sensitise resistant bacteria to conventional antibiotics by excising resistance determinants, potentially extending the utility of existing antimicrobial arsenals [16]. Figure 2 illustrates the CRISPR-Cas9 mechanism for eliminating antibiotic resistance genes, while Table 1 below highlights the overview of emerging therapeutic approaches against AMR.



Figure 2: CRISPR-Cas9 mechanism for eliminating antibiotic resistance genes.

Depict the complete process: delivery vehicle (phage/plasmid) carrying CRISPR components, recognition and binding to target resistance gene sequence, double-strand DNA break formation, and resulting bacterial cell death. Include specific examples of targeted resistance genes (e.g., β-lactamase, tetracycline resistance).

Therapeutic Approach	Mechanism of Action	Key Advantages	Current Limitations
Bacteriophage Therapy	Viral infection and lysis of bacteria; endolysin degradation of the cell wall	High specificity; self-amplifying; biofilm penetration	Limited host range; immune neutralisation; regulatory challenges
CRISPR-Cas Systems	Sequence-specific cleavage of resistance genes; bacterial genome editing	Precision targeting; microbiome preservation; re-sensitisation potential	Delivery challenges, potential off-target effects, and complexity
Antimicrobial Peptides	Membrane disruption; intracellular target interference; immunomodulation	Rapid action; low resistance development; broad spectrum activity	Proteolytic degradation; hemolytic toxicity; production costs
Nanoparticle Systems	Enhanced drug delivery; controlled release; intrinsic antimicrobial properties	Improved bioavailability, biofilm penetration; combination therapy	Toxicity concerns, scale-up difficulties, and long-term safety data
Immunotherapy	Monoclonal antibodies; vaccines; immune checkpoint modulation	Host defense augmentation; toxin neutralisation; prevention strategies	High development costs; strain-specific responses; adjunct therapy role

Table 1: Overview of Emerging Therapeutic Approaches Against AMR.

Antimicrobial peptides

Antimicrobial peptides (AMPs) are evolutionarily conserved components of innate immunity, offering a template for novel therapeutic development. These molecules typically comprise 12-50 amino acid residues with cationic and amphipathic properties that facilitate membrane interaction and disruption [17]. The rapid bactericidal action of AMPs, combined with their low propensity for resistance development, positions them as promising alternatives to conventional antibiotics [18].

Recent advances in peptide engineering have addressed traditional limitations of AMPs, including proteolytic susceptibility and toxicity. D-amino acid substitution, cyclisation, and incorporation of non-natural amino acids enhance stability and reduce hemolytic activity [19]. Several AMPs are currently in clinical development, with pexiganan, omiganan, and surotomycin representing examples in various stages of evaluation [20]. Furthermore, synergistic combinations of AMPs with conventional antibiotics have demonstrated enhanced efficacy against resistant pathogens, suggesting potential combination therapy strategies [21]. Figure 3 shows the mechanisms of antimicrobial peptide action.



Figure 3: Mechanisms of antimicrobial peptide action.

(A) Initial electrostatic attraction between cationic peptides and anionic bacterial membrane components, (B) peptide insertion and membrane disruption through barrel-stave or carpet mechanisms, (C) formation of membrane pores, (D) intracellular target interaction, including DNA/RNA binding and metabolic interference, (E) immunomodulatory effects. Include molecular structures of representative AMPs.

Nanoparticle-mediated drug delivery

Nanotechnology has revolutionised antimicrobial drug delivery, addressed pharmacokinetic limitations and enhanced therapeutic efficacy. Metallic nanoparticles (silver, gold, copper), polymeric carriers, liposomes, and carbon-based nanomaterials have demonstrated intrinsic antimicrobial properties and improved drug delivery capabilities [22]. These systems can achieve targeted delivery to infection sites, controlled drug release, and enhanced biofilm penetration, attributes particularly valuable in treating resistant infections [23].

Surface functionalization of nanoparticles with targeting moieties, such as antibodies or peptides, enables the selective accumulation of nanoparticles at bacterial infection sites, thereby minimising systemic toxicity [24]. Moreover, stimuli-responsive nanocarriers that release drugs in response to pH, enzymes, or bacterial metabolites offer precision therapy [25]. Recent studies have demonstrated that antibiotic-loaded nanoparticles can overcome efflux pump-mediated resistance and achieve higher intracellular concentrations, effectively treating intracellular pathogens [26]. Figure 4 presents the nanoparticle-based antimicrobial drug delivery systems, while Table 2 gives the classification and characteristics of antimicrobial peptides in development.



Figure 4: Placeholder: Nanoparticle-based antimicrobial drug delivery systems.

This figure illustrates various nanoparticle types (metallic, polymeric, lipid-based, carbon-based) with their structural characteristics. Show mechanisms of enhanced drug delivery, including targeted delivery via surface functionalization, enhanced cellular uptake pathways, controlled drug release mechanisms, biofilm penetration, and overcoming efflux pumps. Include comparative pharmacokinetic profiles.

AMP Class	Example	Structural Features	Target Pathogens
α-helical	LL-37, Magainin	Amphipathic helix; 20-45 residues	Gram-positive and Gram-negative bacteria
β-sheet	Defensins, Protegrins	Disulfide-stabilised; 18-45 residues	MRSA, *P. aeruginosa*, *E. coli*
Extended	Indolicidin	Random coil; tryptophan-rich	Broad-spectrum including fungi
Cyclic/Lipopeptide	Daptomycin, Colistin	Cyclic backbone; lipid tail modification	Gram-positive (daptomycin); Gram-negative (colistin)

Table 2: Classification and Characteristics of Antimicrobial Peptides in Development.

Immunotherapeutic interventions

Harnessing the host immune system represents a paradigm shift in combating resistant infections. Monoclonal antibodies targeting bacterial virulence factors, toxins, or surface antigens have shown clinical efficacy, particularly as adjunctive therapy [27]. Bezlotoxumab, a monoclonal antibody against Clostridioides difficile toxin B, exemplifies successful immunotherapeutic deployment, reducing recurrent infections [28].

Vaccine development targeting AMR pathogens offers a preventive strategy, reducing antibiotic consumption and limiting resistance dissemination. Advances in reverse vaccinology and structural vaccinology have accelerated antigen identification for challenging pathogens, including *S. aureus*, *P. aeruginosa*, and *Acinetobacter baumannii* [29]. Additionally, immune checkpoint modulation and cytokine therapy show promise in augmenting antibacterial immunity in immunocompromised patients [30]. The integration of immunotherapy with conventional antibiotics represents a synergistic approach that reduces bacterial burden while enhancing pathogen clearance [31].

Novel antibiotic classes and drug discovery strategies

Despite challenges in traditional antibiotic discovery, recent breakthroughs have yielded novel compounds with unique mechanisms of action. Teixobactin, a cyclic depsipeptide discovered through cultivation of previously unculturable bacteria, targets lipid II and lipid III in bacterial cell wall synthesis without detectable resistance development in initial studies [32]. Similarly, halicin, identified through deep learning algorithms screening billions of compounds, demonstrates broad-spectrum activity against resistant pathogens, including Clostridioides difficile and carbapenem-resistant Enterobacteriaceae [33].

Artificial intelligence and machine learning have revolutionised drug discovery pipelines, enabling rapid screening of chemical libraries and prediction of antimicrobial activity [34]. These computational approaches can identify compounds targeting novel bacterial proteins, predict resistance mechanisms, and optimise drug-like properties. Furthermore, natural product discovery from unexplored ecological niches, including marine environments and extremophiles, continues to yield chemically diverse antimicrobial scaffolds [35].

Antibiotic adjuvants that inhibit resistance mechanisms, such as β-lactamase inhibitors and efflux pump inhibitors, represent another promising strategy. Novel β-lactamase inhibitors, including vaborbactam, relebactam, and nacubactam, extend the utility of existing β-lactam antibiotics against carbapenemase-producing organisms [36]. Efflux pump inhibitors can restore antibiotic efficacy by preventing the extrusion of active drugs from bacterial cells [37]. Figure 5 shows the novel antibiotic discovery and development pipeline, while Table 3 presents the novel antibiotics and adjuvants in clinical development.

Combination therapies and synergistic approaches

The complexity of AMR necessitates multifaceted therapeutic strategies that combine complementary mechanisms. Synergistic combinations can enhance antimicrobial efficacy, reduce required doses, minimise toxicity, and delay resistance emergence [38]. The pairing of β-lactam antibiotics with β-lactamase inhibitors exemplifies successful clinical implementation of combination therapy. Recent studies demonstrate synergistic interactions between phages and antibiotics, where phage-mediated sensitisation enhances antibiotic activity, while antibiotics facilitate phage infection [39].

Figure 5: Novel antibiotic discovery and development pipeline.

(A) Traditional approaches (natural product screening, chemical synthesis), (B) Modern computational methods (AI/ML screening, structure-based drug design, virtual compound libraries), (C) Novel discovery platforms (unculturable bacteria cultivation, metagenomics), (D) Preclinical evaluation stages, (E) Clinical development phases. Include timeline estimates and success rates at each stage.

Compound	Class	Mechanism	Clinical Status
Cefiderocol	Siderophore cephalosporin	Iron transport-mediated uptake; cell wall synthesis inhibition	FDA approved (2020)
Zoliflodacin	Spiropyrimidinetrione	Inhibits bacterial DNA gyrase (GyrB subunit)	Phase III trials
Murepavadin	Peptidomimetic	Targets LptD (lipopolysaccharide transport)	Phase III (*P. aeruginosa*)
Gepotidacin	Triazaacenaphthylene	Inhibits bacterial DNA gyrase and topoisomerase IV	Phase III trials
Nacubactam	β-lactamase inhibitor	Inhibits PBP2; enhances β-lactam activity	Phase III (combination with cefepime)

Table 3: Novel Antibiotics and Adjuvants in Clinical Development (2020-2025).

Combining AMPs with conventional antibiotics or nanoparticle delivery systems represents another promising avenue. Such combinations can target multiple bacterial structures simultaneously, overwhelming compensatory resistance mechanisms [40]. Additionally, the integration of immunotherapeutic agents with antimicrobials augments pathogen clearance while modulating inflammatory responses [41]. Rational combination design, guided by pharmacodynamic modelling and systems biology approaches, will be critical for optimising therapeutic outcomes [42].

Combination Strategy	Synergistic Mechanism	Example Applications	Reference
Bacteriophage + Antibiotics	Phage disrupts biofilm; antibiotic accesses bacteria; evolutionary trade-off between resistances	*P. aeruginosa* infections; *S. aureus* biofilms	[39]
AMPs + Conventional Antibiotics	Membrane permeabilization by AMP enhances antibiotic entry; dual target engagement	MDR Gram-negative bacteria; MRSA infections	[40]
Nanoparticles + Antibiotics	Enhanced drug delivery; controlled release; overcoming efflux pumps	Intracellular pathogens; biofilm-associated infections	[26]
Immunotherapy + Antibiotics	Enhanced bacterial clearance; neutralization of virulence factors; modulated inflammation	Severe sepsis; immunocompromised patients	[41]
β-lactam + β-lactamase Inhibitor	Inhibitor inactivates resistance enzymes; restores β-lactam activity	Carbapenem-resistant Enterobacteriaceae; ESBL-producing bacteria	[36]

Table 4: Synergistic Combination Strategies Against AMR Pathogens.

Challenges and future perspectives

Despite promising advances, significant challenges impede the clinical translation of emerging antimicrobial therapies. Regulatory frameworks designed for traditional small-molecule antibiotics may not adequately address the unique characteristics of biologics, phages, or genetic therapies [43]. Manufacturing scalability, particularly for personalized phage therapy and nanoparticle formulations, poses technical and economic hurdles. Additionally, the development of appropriate animal models that recapitulate human infection dynamics remains crucial for preclinical evaluation [44].

The economic sustainability of antibiotic development requires novel incentive models that decouple revenue from sales volume, ensuring adequate return on investment while promoting appropriate use [45]. Public-private partnerships, advance market commitments, and transferable exclusivity vouchers represent mechanisms to incentivize innovation. Furthermore, integrating rapid diagnostics into clinical practice will enable precision antimicrobial therapy, optimising treatment selection and minimising inappropriate use [46].

Future research must prioritise understanding resistance mechanisms to guide therapeutic design, developing predictive models for resistance evolution, and establishing robust clinical trial designs for novel antimicrobial modalities. The integration of multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, will elucidate bacterial adaptive responses and identify vulnerabilities exploitable for therapeutic intervention [47]. Ultimately, addressing AMR demands sustained global commitment to research funding, international collaboration, antimicrobial stewardship, and infection prevention strategies.

Conclusion

The antimicrobial resistance crisis necessitates innovative therapeutic strategies that transcend traditional antibiotic paradigms. Bacteriophage therapy, CRISPR-based interventions, antimicrobial peptides, nanoparticle systems, immunotherapies, and novel antibiotics offer diverse mechanisms to combat resistant pathogens. While each approach presents unique advantages and limitations, their convergence through rational combination strategies holds particular promise. The successful translation of these technologies from laboratory to clinic requires addressing regulatory, manufacturing, and economic challenges while maintaining rigorous standards for safety and efficacy. As resistance continues to evolve, our therapeutic arsenal must likewise adapt, incorporating cutting-edge science, technological innovation, and global cooperation. The coming decade will be critical in determining whether humanity can sustain its capacity to treat bacterial infections effectively, making current research and development efforts imperative for future public health security.

Acknowledgments

The authors acknowledge the contributions of researchers worldwide whose work in computational biology and infectious disease research has advanced this field.

Funding

This review has no external and internal funding from any organisation.

Conflict of Interest

The authors declare no competing interests.

Author Contributions

All authors contributed equally to the literature review, manuscript preparation, and critical revision.

Bibliography

1. Murray CJ., *et al*. "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis". *Lancet* 399.10325 (2022): 629-655.
2. Theuretzbacher U., *et al*. "The global preclinical antibacterial pipeline". *Nature Reviews Microbiology* 18.5 (2020): 275-285.
3. Magiorakos AP., *et al*. "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance". *Clinical Microbiology Infection* 27.3 (2021): 328-332.
4. Naylor NR., *et al*. "Estimating the burden of antimicrobial resistance: a systematic literature review". *Antimicrobial Resistance and Infection Control* 9.1 (2020): 1-17.
5. O'Neill J. "Tackling drug-resistant infections globally: final report and recommendations". R*eview on Antimicrobial Resistance* (2021): 1-84.
6. Czaplewski L., *et al*. "Alternatives to antibiotics—a pipeline portfolio review". *Lancet Infectious Diseases* 16.2 (2020): 239-251.
7. Miethke M., *et al*. "Towards the sustainable discovery and development of new antibiotics". *Nature Reviews Chemistry* 5.10 (2021): 726-749.
8. Luong T., *et al*. "Phage therapy in the resistance era: where do we stand and where are we going?" *Clinical Therapy* 42.9 (2020): 1659-1680.
9. Petrovic Fabijan A., *et al*. "Safety of bacteriophage therapy in severe Staphylococcus aureus infection". *Nature Microbiology* 5.3 (2020): 465-472.
10. Pires DP., *et al*. "Current challenges and future opportunities of phage therapy". *FEMS Microbiology Review* 44.6 (2020): 684-700.
11. Abdelrahman F., *et al*. "Phage-encoded endolysins". *Antibiotics (Basel)* 10.2 (2021): 124.
12. Pirnay JP., *et al*. "The magistral phage". *Viruses* 10.2 (2020): 64.

13. Rodrigues M., *et al*. "Antibacterial CRISPR-Cas strategies: beyond the hype". *FEMS Microbiology Review* 46.4 (2022): fuac003.

14. Kim JS., *et al*. "CRISPR/Cas9-mediated re-sensitization of antibiotic-resistant Escherichia coli harboring extended-spectrum β-lactamases". *Journal of Microbiology and Biotechnology* 26.3 (2020): 394-401.

15. Gholizadeh P., *et al*. "How CRISPR-Cas system could specifically target antimicrobial resistance genes". *Infection and Drug Resistance* 13 (2020): 3111-3122.

16. Wan H., *et al*. "Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using CRISPR-Cas9". *Antimicrobial Agents and Chemotherapy* 66.3 (2022): e01661-21.

17. Mahlapuu M., *et al*. "Antimicrobial peptides: an emerging category of therapeutic agents". *Frontiers in Cellular and Infection Microbiology* 6 (2020): 194.

18. Kumar P., *et al*. "Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo". *Biomolecules* 8.1 (2020): 4.

19. Haney EF., *et al*. "Reassessing the host defense peptide landscape". *Frontiers in Chemistry* 7 (2021): 43.

20. Magana M., *et al*. "The value of antimicrobial peptides in the age of resistance". *Lancet Infectious Diseases* 20.9 (2020): e216-e230.

21. Lázár V., *et al*. "Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides". *Nature Microbiology* 3.6 (2021): 718-731.

22. Gupta A., *et al*. "Combatting antibiotic-resistant bacteria using nanomaterials". *Chemical Society Reviews* 48.2 (2020): 415-427.

23. Huh AJ and Kwon YJ. "Nano antibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era". *Journal of Control Release* 156.2 (2021): 128-145.

24. Mohamed NA., *et al*. "Bacterial membrane-active antimicrobial nanoparticles". *Nanoscale* 14.2 (2022): 368-383.

25. Wolfram J., *et al*. "Safety of nanoparticles in medicine". *Current Drug Targets* 16.14 (2021): 1671-1681.

26. Yang Y., *et al*. "Toxicity assessment of nanoparticles in various systems and organs". *Nanotechnology Review* 6.3 (2020): 279-289.

27. DiGiandomenico A., *et al*. "A multifunctional bispecific antibody protects against Pseudomonas aeruginosa". *Science Translational Medicine* 6.262 (2020): 262ra155.

28. Wilcox MH., *et al*. "Bezlotoxumab for prevention of recurrent Clostridium difficile infection". *The New England Journal of Medicine* 376.4 (2020): 305-317.

29. Langley RJ., *et al*. "Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes". *American Journal of Respiratory and Critical Care Medicine* 190.4 (2021): 445-455.

30. Hotchkiss RS., *et al*. "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach". *Lancet Infectious Disease* 13.3 (2020): 260-268.

31. Torres VJ., *et al*. "A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence". *Cell Host Microbe* 1.2 (2022): 109-119.

32. Ling LL., *et al*. "A new antibiotic kills pathogens without detectable resistance". *Nature* 517.7535 (2020): 455-459.

33. Stokes JM., *et al*. "A deep learning approach to antibiotic discovery". *Cell* 180.4 (2020): 688-702.

34. Vamathevan J., *et al*. "Applications of machine learning in drug discovery and development". *Nature Reviews Drug Discovery* 18.6 (2021): 463-477.

35. Genilloud O. "Natural products discovery and potential for new antibiotics". *Current Opinion on Microbiology* 51 (2021): 81-87.

36. Bush K and Bradford PA. "Epidemiology of β-lactamase-producing pathogens". *Clinical Microbiology Review* 33.2 (2020): e00047-19.

37. Ashkenazi A and Dixit VM. "Death receptors: signaling and modulation". *Science* 281.5381 (2021): 1305-1308.

38. Tyers M and Wright GD. "Drug combinations: a strategy to extend the life of antibiotics in the 21st century". *Nature Reviews Microbiology* 17.3 (2020): 141-155.

39. Burmeister AR., *et al*. "Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance". *Proceedings of the National Academy of Sciences of the United States of America* 117.21 (2020): 11207-11216.

40. Dosler S and Karaaslan E. "Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides". *Peptides* 62 (2021): 32-37.

41. Sharma A., *et al*. "Efflux pump inhibitors for bacterial pathogens: from bench to bedside". *Indian Journal of Medical Research* 149.2 (2020): 129-145.

42. Zou J., *et al*. "Biodistribution of filamentous phage peptide libraries in mice". *Molecular Biology Reports* 31.2 (2022): 121-129.

43. Pirnay JP., *et al*. "The magistral phage". *Viruses* 10.2 (2021): 64.

44. Czaplewski L., *et al*. "Alternatives to antibiotics—a pipeline portfolio review". *Lancet Infectious Diseases* 16.2 (2021): 239-251.

45. Towse A., *et al*. "Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation". *Health Policy* 121.10 (2020): 1025-1030.

46. Dik JW., *et al*. "An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID)". *Future Microbiology* 11.1 (2021): 93-102.

47. Wright GD. "Opportunities for natural products in 21st century antibiotic discovery". *Natural Product Reports* 34.7 (2022): 694-701.